BPG is committed to discovery and dissemination of knowledge
Articles in Press
7/10/2025 6:13:58 AM | Browse: 15 | Download: 0
Category |
Medicine, Research & Experimental |
Manuscript Type |
Editorial |
Article Title |
Potential risks of histone deacetylase inhibitors in cancer therapeutics and feasible combination therapeutic strategies
|
Manuscript Source |
Invited Manuscript |
All Author List |
Shuai Xiao, Xiao-Zhen Xu, Meng Liao, Dan-Dan Song, Jing-Feng Tang and Ce-Fan Zhou |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
National Natural Science Foundation of China |
32270768 |
National Natural Science Foundation of China |
82273970 |
National Natural Science Foundation of China |
32070726 |
National Natural Science Foundation of China |
82370715 |
Hubei Natural Science Foundation of China |
2024AFB218 |
National Key R&D Program of China |
2023YFC2507904 |
Doctoral Start-up Foundation of Hubei University of Technology |
XJ2022003901 |
|
Corresponding Author |
Ce-Fan Zhou, Professor, School of Life and Health Sciences, Institute of Biomedical Research, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei University of Technology, No. 28 Nanli Road, Wuhan 430068, Hubei Province, China. cefan@hbut.edu.cn |
Key Words |
Histone deacetylase inhibitors; Trichostatin A; Combination therapeutics; Selective inhibitors; Multidrug resistance |
Core Tip |
Histone deacetylase inhibitors (HDACis) have been extensively researched for their potential anticancer effects. However, in addition to their role in inhibiting tumor growth, it has also surprisingly facilitated the metastasis of esophageal squamous cell carcinoma. Clinical studies indicate that the effectiveness of HDACis in treating solid tumors often falls short of expectations, and these inhibitors may inherently carry certain risks. In this article, we examine the potential dangers associated with the clinical use of HDACis, including severe adverse effects, off-target toxicities, multidrug resistance, and limited efficiency in solid tumors. Furthermore, future research should focus on combination therapies, the development of selective or dual-target inhibitors to mitigate the adverse effects of HDACis treatments. |
Citation |
Xiao S, Xu XZ, Liao M, Song DD, Tang JF, Zhou CF. Potential risks of histone deacetylase inhibitors in cancer therapeutics and feasible combination therapeutic strategies. World J Clin Oncol 2025; In press |
 |
Received |
|
2025-04-23 04:11 |
 |
Peer-Review Started |
|
2025-04-23 04:12 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2025-05-14 06:04 |
 |
Revised |
|
2025-05-21 06:33 |
 |
Second Decision |
|
2025-07-10 02:46 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2025-07-10 06:13 |
 |
Articles in Press |
|
2025-07-10 06:13 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
ISSN |
2218-4333 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345